Vaxil Announces Positive Results on CorVax™ in vivo Study
September 08 2020 - 07:40AM
VAXIL BIO LTD. (“
Vaxil” or the
“
Company”) (TSX VENTURE: VXL), an innovative
immunotherapy biotech company specializing in cancer and infectious
diseases, is pleased to announce that it has achieved positive
results for the in vivo (animal) immunogenicity study which
commenced on July 14, 2020.
The experiments, performed at the Medical
Research, Infrastructure, and Health Services Fund of the Tel Aviv
Sourasky Medical Center in Israel (the “Tel Aviv Sourasky
Medical Centre”) were designed to evaluate, in vivo, the
immune response to CorVax™. The results successfully demonstrated
both cellular and humoral responses to multiple signal peptides as
well as to CorVax™, composed of multiple signal peptides. These
results further confirm the potential in the design of Vaxil’s
COVID-19 vaccine candidate and provide additional evidence that it
generates the anticipated immune response. A total of three
injections were inoculated in two mouse strains to better simulate
the human immune environment for which CorVax™ was specifically
designed. Both mouse strains exhibited a humoral response,
developing antibodies as early as 10 days after last injection.
Both strains also displayed activated T cells against the signal
peptides.
“We are delighted with these results, which
indicate that further work is warranted to solidify the evidence
behind the success of this study,” said Dr. David Hagin, Director
of the Allergy and Clinical Immunology Unit at the Tel Aviv Medical
Sourasky Center, and continued “from the outset, I was intrigued by
Vaxil’s novel solution to a potential COVID-19 vaccine. We are
seeing hundreds of patients at our hospital, daily, and therefore,
to be involved in developing a potential solution to a global
pandemic is particularly fulfilling.”
“We are very pleased with the outcome of this
study, and will now weigh next steps to continue to produce more
data, eventually to achieve approval to launch a clinical trial,”
said David Goren, Vaxil’s Chairman and Chief Executive Officer, and
continued, “our collaboration with Dr. Hagin and his team at the
Tel Aviv Sourasky Medical Centre is extremely effective and I thank
Dr. Hagin and his team for their outstanding commitment and
professionalism.”
The study was performed by a third-party world
leading tertiary medical center according to Israeli regulations
and the results are expected to be published in the future.
We expect to provide a further update within the
next eight weeks.
ABOUT VAXIL
Vaxil is an Israeli immunotherapy biotech
company focused on its novel approach to targeting prominent cancer
markers and infectious diseases. Its lead product ImMucin™
successfully completed a Phase 1/2 clinical trial in multiple
myeloma for which it received orphan drug status from the FDA and
EMA. The company aims to continue to develop ImMucin™, a COVID-19
and a tuberculosis vaccine / treatment that has demonstrated
promising preliminary results with further preclinical evaluation
planned. Additional indications and mAb candidates are under
evaluation as immuno-oncology and infectious disease treatments
alone and in combination with other treatments.
Vaxil exploits the unique properties of signal
peptide domains on crucial proteins to develop targeted therapies
against cancer targets and infectious disease pathogens. These
signal peptide domains are identified by VaxHit™, Vaxil’s
proprietary bioinformatic approach. These signal pepdies induce a
robust T- and B-cell response across wide and varied HLA subtypes,
while acting as true, universal neoantigens. The peptide platform
targets these cells by “educating” or specifically activating the
immune system to recognize and attack the affected cells. In
addition, Vaxil’s mAb platform directly recognizes the target
protein expressed on malignant cells and recruits other elements of
the immune system to lyse those cells.
The Company is not making any express or implied
claims that it has completed developing or will be successful in
developing a COVID-19 (or SARS-CoV-2) vaccine at this time.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Disclaimer: The Company cautions that COVID-19
Vaccine Development is still under early stage research and
development and is not making any express or implied claims that it
has the ability to eliminate the COVID-19 virus at this time. The
TSX Venture Exchange Inc. has in no way passed upon the merits of
the Company and has neither approved nor disapproved the contents
of this press release. This news release contains forward-looking
information, which involves known and unknown risks, uncertainties
and other factors that may cause actual events to differ materially
from current expectation. Important factors - including the
availability of funds, the results of financing efforts, the
results of exploration activities -- that could cause actual
results to differ materially from the Company's expectations are
disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. This press
release does not constitute an offer to sell or a solicitation of
an offer to sell any of the securities described herein in the
United States or elsewhere. These securities have not been, and
will not be, registered in the United States Securities Act of
1933, as amended, or any state securities laws, and may not be
offered or sold in the United States or to U.S. persons unless
registered or exempt therefrom.
CONTACT INFORMATIONFor further information please
visit http://vaxil-bio.com/ or contact: David Goren, CEO
-- info@vaxil-bio.com, +972 (52) 720-6000
Vaxil Bio (TSXV:VXL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Vaxil Bio (TSXV:VXL)
Historical Stock Chart
From Mar 2023 to Mar 2024